GPR35 and sclerosing cholangitis: The potential of targeting GPR35 in a therapeutic context is supported in part by genetic associations that have suggested roles in diseases including ulcerative colitis and primary sclerosing cholangitis (Ellinghaus et al.,2013; Yang et al.,2015), and GPR35 is highly expressed in regions of, particularly, the lower gut and colon and by various white cell groups, including numerous dendritic cell and monocyte populations.